Kidney Cancer Trial Results
Expanding the Playing Field: Immune-Based Therapy Shows Potential for Lung, Other Cancers
(Posted: 06/15/2012) - Results from two early-phase clinical trials presented at the 2012 American Society of Clinical Oncology annual meeting provide further evidence that priming the immune system to attack tumors has potential as a treatment for certain cancers.
![](https://webarchive.library.unt.edu/web/20121006235807im_/http://www.cancer.gov/images/spacer.gif)
Denosumab Effective for Multiple Myeloma and Solid Tumors
(Posted: 06/08/2011) - Results from a randomized phase III trial of denosumab to prevent skeletal related events in several types of cancer were published online February 22, 2011, in the Journal of Clinical Oncology (JCO).
![](https://webarchive.library.unt.edu/web/20121006235807im_/http://www.cancer.gov/images/spacer.gif)
When Combined with Chemotherapy, Bevacizumab Is Associated with Increased Risk of Death
(Posted: 03/30/2011) - Cancer patients who receive the targeted therapy bevacizumab (Avastin) in combination with chemotherapy are at increased risk of serious side effects that may lead to death, according to a meta-analysis of 16 clinical trials that was published February 2, 2011, in JAMA.
![](https://webarchive.library.unt.edu/web/20121006235807im_/http://www.cancer.gov/images/spacer.gif)
Sorafenib Delays Progression of Metastatic Kidney Cancer
(Posted: 02/07/2007, Updated: 06/08/2009) - The targeted drug sorafenib (Nevaxar®), which delays disease progression in patients with metastatic kidney cancer, may also improve survival of such patients, according to the May 18, 2009, Journal of Clinical Oncology.
![](https://webarchive.library.unt.edu/web/20121006235807im_/http://www.cancer.gov/images/spacer.gif)
Everolimus Extends Progression-Free Survival in Advanced Kidney Cancer
(Posted: 07/30/2008) - A phase III trial testing the drug everolimus in patients with advanced kidney cancer was stopped after an interim analysis showed a significant improvement in progression-free survival, the drug's manufacturer, Novartis, reported February 28, 2008.
![](https://webarchive.library.unt.edu/web/20121006235807im_/http://www.cancer.gov/images/spacer.gif)
(Posted: 06/15/2012) - Results from two early-phase clinical trials presented at the 2012 American Society of Clinical Oncology annual meeting provide further evidence that priming the immune system to attack tumors has potential as a treatment for certain cancers.
![](https://webarchive.library.unt.edu/web/20121006235807im_/http://www.cancer.gov/images/spacer.gif)
Denosumab Effective for Multiple Myeloma and Solid Tumors
(Posted: 06/08/2011) - Results from a randomized phase III trial of denosumab to prevent skeletal related events in several types of cancer were published online February 22, 2011, in the Journal of Clinical Oncology (JCO).
![](https://webarchive.library.unt.edu/web/20121006235807im_/http://www.cancer.gov/images/spacer.gif)
When Combined with Chemotherapy, Bevacizumab Is Associated with Increased Risk of Death
(Posted: 03/30/2011) - Cancer patients who receive the targeted therapy bevacizumab (Avastin) in combination with chemotherapy are at increased risk of serious side effects that may lead to death, according to a meta-analysis of 16 clinical trials that was published February 2, 2011, in JAMA.
![](https://webarchive.library.unt.edu/web/20121006235807im_/http://www.cancer.gov/images/spacer.gif)
Sorafenib Delays Progression of Metastatic Kidney Cancer
(Posted: 02/07/2007, Updated: 06/08/2009) - The targeted drug sorafenib (Nevaxar®), which delays disease progression in patients with metastatic kidney cancer, may also improve survival of such patients, according to the May 18, 2009, Journal of Clinical Oncology.
![](https://webarchive.library.unt.edu/web/20121006235807im_/http://www.cancer.gov/images/spacer.gif)
Everolimus Extends Progression-Free Survival in Advanced Kidney Cancer
(Posted: 07/30/2008) - A phase III trial testing the drug everolimus in patients with advanced kidney cancer was stopped after an interim analysis showed a significant improvement in progression-free survival, the drug's manufacturer, Novartis, reported February 28, 2008.
![](https://webarchive.library.unt.edu/web/20121006235807im_/http://www.cancer.gov/images/spacer.gif)